MDMA-assisted therapy for moderate to severe PTSD: a randomized, placebo-controlled phase 3 trial - (Mitchell, et al, 2023)

Results from the phase 3 placebo-controlled MAPP2 trial show that MDMA-assisted therapy reduces post-traumatic stress disorder (PTSD) symptoms and functional impairment in a diverse population with moderate to severe PTSD.